Apotex Health Corp. ("Apotex" or the "Company") has successfully closed its upsized initial public offering (IPO) of 62,291,670 common shares at $24.00 per share, generating gross proceeds of $1,495,000,080. The offering consisted of a treasury component and a secondary component, with the over-allotment option exercised in full.
Details of the Offering
The IPO included a treasury offering by Apotex of 35,416,666 common shares, raising $849,999,984 for the company. A secondary offering by SK Capital Partners and other selling shareholders involved 26,875,004 common shares, yielding $645,000,096 for those sellers. Among the secondary shares, 8,125,000 were sold through the full exercise of the over-allotment option. Apotex did not receive proceeds from the over-allotment shares.
Underwriters and Advisors
The offering was managed by a syndicate led by RBC Capital Markets, TD Securities Inc., and Scotiabank as co-lead managers, joint global coordinators, and joint lead bookrunners. BMO Capital Markets and Jefferies Securities Inc. served as joint bookrunners, with CIBC Capital Markets, ATB Cormark Capital Markets, Desjardins Capital Markets, National Bank Capital Markets, MUFG, Raymond James, Bloom Burton Securities Inc., Canaccord Genuity Corp., Stifel, and Paradigm Capital Inc. as co-managers.
Goodmans LLP acted as Canadian legal counsel to Apotex, while Stikeman Elliott LLP represented the underwriters in Canada. Kirkland & Ellis LLP served as U.S. legal counsel to Apotex, and Skadden, Arps, Slate, Meagher & Flom LLP advised the underwriters on U.S. matters.
Listing and Regulatory Details
The common shares are listed on the Toronto Stock Exchange under the symbol "APTX." The offering was completed under a supplemented PREP prospectus dated June 10, 2026, filed with securities regulators across Canadian provinces and territories. The prospectus is available on SEDAR+.
No securities regulatory authority has approved or disapproved the content of this release. The securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction where such activity would be unlawful.
